Roche’s Hemlibra gets speedy FDA review for wider use

Share this post

ZURICH (Reuters) – Roche’s hemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company’s plans to muscle in on turf dominated by rivals including Shire.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply